Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma.

IF 3.6 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Hannah C Byren, Angela Holzer, Alexander Müller, Klaus Korn, Marija Backovic, Ellen G Harrer, Silke Bergmann, Thomas Harrer, Frank Neipel
{"title":"Increased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma.","authors":"Hannah C Byren, Angela Holzer, Alexander Müller, Klaus Korn, Marija Backovic, Ellen G Harrer, Silke Bergmann, Thomas Harrer, Frank Neipel","doi":"10.1099/jgv.0.002044","DOIUrl":null,"url":null,"abstract":"<p><p>Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and <i>in vitro</i> HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.</p>","PeriodicalId":15880,"journal":{"name":"Journal of General Virology","volume":"105 11","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of General Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1099/jgv.0.002044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi's sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and in vitro HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.

卡波西肉瘤缓解期人类疱疹病毒-8 中和反应增强
人类疱疹病毒-8(HHV-8)又称卡波西肉瘤相关疱疹病毒,是一种人类致癌疱疹病毒,可导致包括卡波西肉瘤(KS)在内的多种疾病。卡波济氏肉瘤的发病率差异很大,但随着人类免疫缺陷病毒-1(HIV-1)的合并感染,发病率会大幅上升,甚至在 HIV-1 在非洲流行之前,它就已成为 HIV-1 患者和撒哈拉以南非洲男性最常见的癌症之一。研究表明,HHV-8 感染者的血清中存在中和抗体,这些抗体很可能是针对病毒裂解表面糖蛋白的,如糖蛋白 K8.1(gpK8.1)和 gHgL。对58份HHV-8阳性血清样本进行了gpK8.1和gHgL结合抗体水平和体外HHV-8中和能力检测。然后根据疾病状态(包括无症状感染、活动性 KS 和 KS 缓解期)对每个样本进行分类,并比较疾病组之间的三个测量参数。我们发现,感染患者血清中的中和能力会随着 KS 的缓解而增加。有趣的是,在疾病活动期和缓解期,针对 gpK8.1 的抗体也有所增加,但针对 gHgL 的抗体却没有增加。对单个患者的中和能力和抗体水平进行比较后发现,主要针对 gHgL 的抗体水平与舌下卡波西肉瘤(SLK)细胞的血清中和反应相关。吸附人血清中的 gHgL 或 gpK8.1 抗体可消除 SLK 细胞中的中和反应,但血清中抗体的一些非特异性清除意味着对这一结果的解释应谨慎。综合来看,这些结果表明糖蛋白(如 gHgL)是中和抗体的靶标。此外,我们的数据还表明,KS 的恢复与中和能力的提高有关,这表明中和抗体可能有助于 KS 的缓解。然而,要阐明这种关系,还需要进一步的工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of General Virology
Journal of General Virology 医学-病毒学
CiteScore
7.70
自引率
2.60%
发文量
91
审稿时长
3 months
期刊介绍: JOURNAL OF GENERAL VIROLOGY (JGV), a journal of the Society for General Microbiology (SGM), publishes high-calibre research papers with high production standards, giving the journal a worldwide reputation for excellence and attracting an eminent audience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信